# Concept: Capitalised research and development expense for bioindustry

## Bilingual Labels
- **EN**: Capitalised research and development expense for bioindustry
- **KO**: 장부금액, 자산화된 연구개발비, 바이오 제약

- **ID**: dart:CapitalisedResearchAndDevelopmentExpenseForBioindustry

## Reported Numerical Facts

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 252,749,745,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 243,308,510,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 252,749,745,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 243,308,510,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 60,565,393,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 82,998,796,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 60,565,393,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 82,998,796,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 1,427,472,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 1,370,434,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 454,852,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 433,193,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 21,295,566,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 25,795,991,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 18,340,723,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 21,974,853,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2025-03-31**
  - **Value**: 1,484,509,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 827,352,351,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 813,705,436,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 829,297,477,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 815,650,562,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 137,959,832,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 142,611,879,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 137,959,833,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 142,611,879,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 90,107,364,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 95,145,143,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 90,107,364,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 95,145,143,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 6,435,411,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 924,391,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 6,435,411,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 924,391,000 (decimals: -3)

### **Context (Labels): Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 1,397,893,134,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 1,405,860,580,000 (decimals: -3)

### **Context (Labels): Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 1,395,910,798,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 1,403,047,327,000 (decimals: -3)

## Accounting Standard References
- **Standard**: 제약․바이오 기업의 연구개발비 회계처리 관련 감독지침 nan, Paragraph: nan

---
*Source Document: entity00413046_2025-03-31.xbrl*
## Embeddable Text (for FAISS)
```text
Concept: Capitalised research and development expense for bioindustry
Bilingual Labels
 EN: Capitalised research and development expense for bioindustry
 KO: 장부금액, 자산화된 연구개발비, 바이오 제약
 ID: dart:CapitalisedResearchAndDevelopmentExpenseForBioindustry
Reported Numerical Facts
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 252,749,745,000 (decimals: 3)
 Period: 20250331
   Value: 243,308,510,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 252,749,745,000 (decimals: 3)
 Period: 20250331
   Value: 243,308,510,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 60,565,393,000 (decimals: 3)
 Period: 20250331
   Value: 82,998,796,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 60,565,393,000 (decimals: 3)
 Period: 20250331
   Value: 82,998,796,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 1,427,472,000 (decimals: 3)
 Period: 20250331
   Value: 1,370,434,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 454,852,000 (decimals: 3)
 Period: 20250331
   Value: 433,193,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 21,295,566,000 (decimals: 3)
 Period: 20250331
   Value: 25,795,991,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 18,340,723,000 (decimals: 3)
 Period: 20250331
   Value: 21,974,853,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20250331
   Value: 1,484,509,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 827,352,351,000 (decimals: 3)
 Period: 20250331
   Value: 813,705,436,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 829,297,477,000 (decimals: 3)
 Period: 20250331
   Value: 815,650,562,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 137,959,832,000 (decimals: 3)
 Period: 20250331
   Value: 142,611,879,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 137,959,833,000 (decimals: 3)
 Period: 20250331
   Value: 142,611,879,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 90,107,364,000 (decimals: 3)
 Period: 20250331
   Value: 95,145,143,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 90,107,364,000 (decimals: 3)
 Period: 20250331
   Value: 95,145,143,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 6,435,411,000 (decimals: 3)
 Period: 20250331
   Value: 924,391,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 6,435,411,000 (decimals: 3)
 Period: 20250331
   Value: 924,391,000 (decimals: 3)
Context (Labels): Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 1,397,893,134,000 (decimals: 3)
 Period: 20250331
   Value: 1,405,860,580,000 (decimals: 3)
Context (Labels): Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 1,395,910,798,000 (decimals: 3)
 Period: 20250331
   Value: 1,403,047,327,000 (decimals: 3)
Accounting Standard References
 Standard: 제약․바이오 기업의 연구개발비 회계처리 관련 감독지침 nan, Paragraph: nan
Source Document: entity00413046_20250331.xbrl
```